Cargando…
Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome
Introduction: Primary obstetric antiphospholipid syndrome (OAPS) is defined by specific morbidities and/or losses of pregnancy in the presence of persistent antiphospholipid antibodies (aPL). This variant of APS is usually treated during pregnancy and the post-partum period. Data on occurrence of th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068935/ https://www.ncbi.nlm.nih.gov/pubmed/35529433 http://dx.doi.org/10.3389/fphar.2022.824775 |
_version_ | 1784700325849989120 |
---|---|
author | Niznik, Stanley Rapoport, Micha J. Avnery, Orly Lubetsky, Aharon Shavit, Ronen Ellis, Martin H. Agmon-Levin, Nancy |
author_facet | Niznik, Stanley Rapoport, Micha J. Avnery, Orly Lubetsky, Aharon Shavit, Ronen Ellis, Martin H. Agmon-Levin, Nancy |
author_sort | Niznik, Stanley |
collection | PubMed |
description | Introduction: Primary obstetric antiphospholipid syndrome (OAPS) is defined by specific morbidities and/or losses of pregnancy in the presence of persistent antiphospholipid antibodies (aPL). This variant of APS is usually treated during pregnancy and the post-partum period. Data on occurrence of thrombotic event during long term follow-up of OAPS patients is limited. Methods: A multi-centre retrospectively cohort of female patients with primary APS (pAPS) was assembled during 2004–2019. Patients were grouped according to disease presentation as pure OAPS or thrombotic APS (tAPS) for those presenting with thrombosis. Clinical and serological data were compared between groups. Results: Of 219 pAPS female patients 67 (30.6%) were diagnosed with OAPS and 152 (69.4%) with tAPS. During >10 years of follow-up 24/67 (35.8%) OAPS and 71/152 (50%) tAPS suffered a new thrombotic event (p = 0.06), while obstetric morbidity was more likely in the OAPS group (31.3 vs. 10.5%, p < 0.001) respectively. Among patients with OAPS at presentation heart valve disease and the presence of ANA were related to thrombosis following diagnosis (25 vs. 4.7%, p = 0.02; and 45.8 vs. 20.8%, p = 0.04 respectively). Conclusion: Thrombotic event following diagnosis were common among female patients with pAPS regardless of disease presentation. Heart valve disease and ANA positivity may be risk factors for thrombosis during follow-up of patients presenting with pure OAPS. |
format | Online Article Text |
id | pubmed-9068935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90689352022-05-05 Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome Niznik, Stanley Rapoport, Micha J. Avnery, Orly Lubetsky, Aharon Shavit, Ronen Ellis, Martin H. Agmon-Levin, Nancy Front Pharmacol Pharmacology Introduction: Primary obstetric antiphospholipid syndrome (OAPS) is defined by specific morbidities and/or losses of pregnancy in the presence of persistent antiphospholipid antibodies (aPL). This variant of APS is usually treated during pregnancy and the post-partum period. Data on occurrence of thrombotic event during long term follow-up of OAPS patients is limited. Methods: A multi-centre retrospectively cohort of female patients with primary APS (pAPS) was assembled during 2004–2019. Patients were grouped according to disease presentation as pure OAPS or thrombotic APS (tAPS) for those presenting with thrombosis. Clinical and serological data were compared between groups. Results: Of 219 pAPS female patients 67 (30.6%) were diagnosed with OAPS and 152 (69.4%) with tAPS. During >10 years of follow-up 24/67 (35.8%) OAPS and 71/152 (50%) tAPS suffered a new thrombotic event (p = 0.06), while obstetric morbidity was more likely in the OAPS group (31.3 vs. 10.5%, p < 0.001) respectively. Among patients with OAPS at presentation heart valve disease and the presence of ANA were related to thrombosis following diagnosis (25 vs. 4.7%, p = 0.02; and 45.8 vs. 20.8%, p = 0.04 respectively). Conclusion: Thrombotic event following diagnosis were common among female patients with pAPS regardless of disease presentation. Heart valve disease and ANA positivity may be risk factors for thrombosis during follow-up of patients presenting with pure OAPS. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9068935/ /pubmed/35529433 http://dx.doi.org/10.3389/fphar.2022.824775 Text en Copyright © 2022 Niznik, Rapoport, Avnery, Lubetsky, Shavit, Ellis and Agmon-Levin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Niznik, Stanley Rapoport, Micha J. Avnery, Orly Lubetsky, Aharon Shavit, Ronen Ellis, Martin H. Agmon-Levin, Nancy Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome |
title | Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome |
title_full | Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome |
title_fullStr | Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome |
title_full_unstemmed | Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome |
title_short | Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome |
title_sort | long term follow up of patients with primary obstetric antiphospholipid syndrome |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068935/ https://www.ncbi.nlm.nih.gov/pubmed/35529433 http://dx.doi.org/10.3389/fphar.2022.824775 |
work_keys_str_mv | AT niznikstanley longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome AT rapoportmichaj longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome AT avneryorly longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome AT lubetskyaharon longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome AT shavitronen longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome AT ellismartinh longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome AT agmonlevinnancy longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome |